Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$3.60 USD
-0.09 (-2.44%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.60 0.00 (0.00%) 5:36 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGHT 3.60 -0.09(-2.44%)
Will SGHT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGHT
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
Glaukos Builds Dual Growth Engines Amid Market Headwinds
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates
Other News for SGHT
SGHT forms Stochastic Buy Signal on September 18
Technical picture remains unchanged for SGHT after it falls 2.01% on September 17
Needham medtech & diagnostics analysts hold analyst/industry conference call
SGHT's price falls by 0.85% on September 16, though its technical setup remains stable.
SGHT: Sight Sciences' OMNI System Shows Promising Results in Glaucoma Treatment